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Introduction
RNA interference (RNAi) is a highly efficient gene-silencing 
mechanism in which a small interfering RNA (siRNA) binds a 
target mRNA, guiding mRNA cleavage via an RNA-induced 
silencing complex (RISC).1,2 This biological phenomenon 
is widely used as a genetic tool in biomedical research. 
Advances in RNA chemistry have expanded siRNA applica-
tions toward therapeutic development, with robust efficacy 
seen in phase 2 clinical trials for liver diseases (e.g., trans-
thyretin amyloidosis).3–5
Despite its prevalence in biomedical research, the use of 
RNAi in neurodegenerative research has been limited.6 There 
is a significant unmet need for simple, effective, and nontoxic 
siRNA delivery methods to modulate gene expression in pri-
mary neurons and brain. A range of approaches has been 
evaluated,7 including AAV viruses,8,9 peptide conjugates,10 
oligonucleotide formulations,11 infusion of naked or slightly 
modified siRNAs,12,13 ultrasound,14 and convection-enhanced 
based delivery.15 None of these approaches has received wide 
acceptance due to toxicity, a requirement for extensive repeti-
tive dosing, and/or limited spatial distribution. Lipofection and 
electroporation of siRNAs are challenging in primary neurons 
due to low transfection efficiencies and their extreme sensitiv-
ity to external manipulation.16 Delivery of siRNA precursors 
(Lentiviruses and AAV) has been used successfully, but viral 
transduction cannot readily be turned off and requires exten-
sive formulation and experimental optimization to achieve 
reproducible, nontoxic silencing in neuronal cells.17–22
In this study, we describe the delivery, distribution, and 
silencing capacity of hydrophobically modified siRNAs 
(hsiRNAs) in primary neurons and in mouse brain. hsiR-
NAs are  siRNA-antisense hybrids containing numerous 
chemical modifications (see Figure 1 and Supplementary 
Table S1 for exact chemical composition of compounds 
used) designed to promote biodistribution and stability while 
minimizing immunogenicity. As a model for our studies, we 
silenced the huntingtin (Htt) gene, the causative gene in Hun-
tington’s disease (HD). HD is an autosomal-dominant neu-
rodegenerative disorder caused by a toxic expansion in the 
CAG repeat region of the huntingtin gene leading to a variety 
of molecular and cellular consequences. Tetrabenazine, the 
only FDA-approved therapy for HD, seeks to alleviate disease 
symptoms but does not treat the actual problem: the gain of 
toxic function caused by mutant Htt. Recent studies suggest 
that transient neuronal knockdown of Htt mRNA can reverse 
disease progression without compromising normal cellular 
function in vivo.23 At present, RNA interference via siRNA or 
antisense oligonucleotide is one of the most promising thera-
peutic approaches for transient Htt mRNA silencing.
We performed a screen of hsiRNAs targeting Htt mRNA 
and identified multiple functional compounds. We showed that 
primary neurons internalize hsiRNA added directly to the cul-
ture medium, with membrane saturation occurring by 1 hour. 
Direct uptake in neurons induces potent and  long-lasting 
silencing of Htt mRNA for up to 3 weeks in vitro without 
major detectable effects on neuronal viability. Additionally, a 
single injection of unformulated (without cationic lipid or AAV 
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Applications of RNA interference for neuroscience research have been limited by a lack of simple and efficient methods to 
deliver oligonucleotides to primary neurons in culture and to the brain. Here, we show that primary neurons rapidly internalize 
hydrophobically modified siRNAs (hsiRNAs) added directly to the culture medium without lipid formulation. We identify 
functional hsiRNAs targeting the mRNA of huntingtin, the mutation of which is responsible for Huntington’s disease, and 
show that direct uptake in neurons induces potent and specific silencing in vitro. Moreover, a single injection of unformulated 
hsiRNA into mouse brain silences Htt mRNA with minimal neuronal toxicity. Thus, hsiRNAs embody a class of therapeutic 
oligonucleotides that enable simple and straightforward functional studies of genes involved in neuronal biology and 
neurodegenerative disorders in a native biological context.
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formulation) Htt hsiRNA into mouse brain silences Htt mRNA 
with minimal neuronal toxicity.
Efficient gene silencing in primary neurons and in vivo 
upon direct administration of unformulated hsiRNA repre-
sents a significant technical advance in the application of 
RNAi to neuroscience research, enabling technically achiev-
able genetic manipulation in a native, biological context.
Results
hsiRNAs are efficiently internalized by primary neurons
hsiRNA is an asymmetric compound composed of a 
15-nucleotide modified RNA duplex with a single-stranded 
3′ extension on the guide strand (Figure 1a and Supple-
mentary Table S1).24,25 Pyrimidines in the hsiRNA are modi-
fied with 2′-O-methyl (passenger strand) or 2′-fluoro (guide 
strand) to promote stability, and the 3′ end of the passenger 
strand is conjugated to a hydrophobic teg-Chol (tetraethyl-
ene glycol cholesterol) to promote membrane binding and 
association.26 The single-stranded tail contains hydrophobic 
phosphorothioate linkages and promotes cellular uptake by 
a mechanism similar to that of antisense oligonucleotides.27 
The presence of phosphorothioates, ribose modifications, 
and a cholesterol conjugate contribute to overall hydropho-
bicity and are essential for compound stabilization and effi-
cient cellular internalization.
Previous studies have shown that hydrophobically modified 
siRNAs bind to a wide range of cells and is readily internalized 
without the requirement for a transfection reagent.26,28,29 Here, 
we evaluated whether asymmetric hydrophobically modified 
siRNAs are efficiently internalized by primary neurons. We 
found that, when added to the culture medium, Cy3-labeled 
hsiRNAs rapidly associated with primary cortical neurons 
(Figure 1b). These Cy3-labeled hsiRNAs were observed in 
every cell in the culture, demonstrating efficient and uniform 
uptake. Initially, hsiRNAs mainly associate with neurites and, 
over time, accumulate in the cell bodies. Treatment of primary 
neurons with a previously identified hsiRNA targeting Ppib26,28 
(encodes cyclophilin B) reduced target mRNA levels by 90%, 
further supporting that the observed compound internaliza-
tion results in potent gene silencing (Figure 1c).
Identification of hsiRNAs that silence huntingtin mRNA
Robust uptake and efficacy observed with hsiRNAs in primary 
cortical neurons encouraged us to identify functional com-
pounds that target Htt mRNA, the single gene responsible 
for the development of Huntington’s disease. The hsiRNA's 
extensive chemical scaffold26,28 is essential for stability, mini-
mization of innate immune response,30,31 and cellular inter-
nalization but imposes significant restrictions on sequence 
space by potentially interfering with the compound’s RISC-
entering ability. To maximize the likelihood of identifying func-
tional Htt hsiRNAs and to evaluate the hit rate for this type of 
chemistry, we designed (using conventional criteria described 
in Materials and Methods) and synthesized hsiRNAs target-
ing 94 sites across the human Htt mRNA (Supplementary 
Table S1). The panel of hsiRNAs was initially screened for 
efficacy in HeLa cells by adding hsiRNA directly to the culture 
Figure 1 hsiRNAs are efficiently internalized by primary cortical neurons. (a) Schematic structure of hsiRNAs. A double-stranded 
oligonucleotide with single-stranded, phosphorothioated tale. 2′-O-methyl and 2′-fluoro modifications, conjugated to teg-chol. (b) Fluorescent 
images of primary cortical neurons incubated with 0.5 µmol/l Cy3-PPIB hsiRNA (red). Nuclei counterstained with Hoechst dye (blue), imaged 
on Zeiss confocal microscope, ×63. Bar = 10 µm. Images are representative, results confirmed in five separate experiments. (c) Primary 
cortical neurons incubated for 72 hours with hsiRNA targeting Ppib at concentrations shown. Level of Ppib mRNA was measured using 
QuantiGene (Affymetrix) normalized to housekeeping gene, Htt, presented as percent of untreated control (n = 3 wells, mean ± SD). NTC, 
nontargeting control (0.75 µmol/l). Graph is representative, results confirmed in three separate experiments.
2′-O-methyl RNA
2′-fluoro RNA
Sense strand
Antisense strand
120 PPIB-hsiRNA
NTC100
80
60
40
Cy
clo
ph
illi
n 
B 
m
RN
A 
ex
pr
es
sio
n
(%
 of
 un
tre
ate
d c
on
tro
l,
m
e
a
n
 ±
 
SD
)
20
0
NTC 0 0.2 0.4
[hsiRNa], µmol/l
0.6 0.8
Cholesterol
DIC (63×) Fluorescence (63×) Zoom
1 
ho
ur
3 
ho
ur
s
30
 h
ou
rs
TEG linker
Phosphorothioate
5′-phosphate
a
c
b
www.moleculartherapy.org/mtna
hsiRNAs Silence Htt in Neurons and Mouse Brain
Alterman et al.
3
medium (without lipofection or electroporation) to a final con-
centration of 1.5 µmol/l and evaluating impact on levels of 
Htt and housekeeping (Ppib) gene mRNA expression using 
the QuantiGene (Affymetrix, Santa Clara, CA) assay. At this 
concentration, 24 hsiRNAs reduced Htt mRNA levels to less 
than 50% of control levels, including 7 hsiRNAs that reduced 
Htt mRNA levels below 30% of control (Figure 2a). Unlike 
unmodified siRNA libraries, creating a library with extensive 
2’-O-methyl and 2’-fluoro modifications introduces additional 
constraints on sequence selection. As a result, hit rates for 
modified siRNA screens are lower than that seen for conven-
tional unmodified siRNA.32–35 Functional hsiRNAs targeted 
sites distributed throughout the mRNA, except the distal end 
of the 3′ UTR, which later was shown to be part of the alter-
native Htt gene isoform36 not expressed in HeLa cells (data 
not shown). Discounting the ~32 hsiRNAs targeting long 3′ 
UTR sites absent from the Htt isoform in HeLa cells, almost 
40% of hsiRNAs showed some level of activity at 1.5 µmol/l, 
demonstrating that the evaluated chemical scaffold is well 
tolerated by the RNAi machinery and a functional compound 
can be easily identified against a wide range of targets.
Half-maximal inhibitory concentrations (IC50) for passive 
uptake of hsiRNAs ranged from 82 to 766 nmol/l (Supple-
mentary Table S1 and Figure S1). In lipid-mediated deliv-
ery, eight of the most active hsiRNAs had IC50 values ranging 
from 4 to 91 pmol/l (Supplementary Table S1). The best 
clinically active siRNAs are usually characterized by IC50 
values in the low pmol/l range.37 An ability to identify highly 
potent compounds with low picomolar IC50 values suggests 
that the hsiRNA chemical scaffold does not interfere with 
siRNA biological activity in selected compounds. The most 
potent hsiRNA targeting position, 10150 (HTT10150), and 
an unmodified conventional siRNA version of HTT10150 
showed similar IC50 values in lipid-mediated delivery (4 and 
13 pmol/l respectively, Figure 2c), further confirming that the 
hsiRNA chemical scaffold does not interfere with RISC load-
ing or function. Only the fully modified hsiRNA, and not the 
unmodified version, silenced Htt mRNA by passive uptake 
(Figure 2b). Thus, the chemical scaffold described here does 
not interfere with RISC assembly and is sufficient to support 
unformulated compound uptake and efficacy. HTT10150 was 
used for subsequent studies.
Figure 2 Systematic screen identifies functional hsiRNAs targeting huntingtin mRNA. (a) Huntingtin mRNA levels in HeLa cells treated 
for 72 hours with 94 hsiRNAs (1.5 µmol/l) were quantified using QuantiGene and normalized to the housekeeping gene Ppib. Data are presented 
as percent of untreated control (n = 3 wells, mean ± SD). Gray area represents range of huntingtin mRNA levels encompassing untreated 
and nontargeting hsiRNA controls. Red bars indicate compounds selected for further analysis. Compound sequence, chemical composition, 
and level of silencing are shown in Supplementary Table S1. Graph is representative, results confirmed in two separate experiments. (b,c) 
Dose–response analysis of huntingtin mRNA levels in HeLa cells treated with HTT10150 hsiRNA (circles) or unmodified siRNA (squares) 
added to culture medium in the (b) absence (modified HTT10150 IC50 = 82.2 nmol/l) or (c) presence (modified HTT10150 IC50 = 0.004 nmol/l, 
unmodified HTT10150 IC50 = 0.013 nmol/l), of cationic lipids for 72 hours. Huntingtin mRNA was measured as described in a (n = 3 wells, 
mean ± SD). IC50 values were calculated as described in Materials and Methods and are presented in Supplementary Table S1. Graph is 
representative, results for modified siRNA confirmed in three separate experiments (in both absence and presence of cationic lipids), results for 
unmodified siRNA confirmed in two separate experiments (in both absence and presence of cationic lipids).
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Potent and specific silencing with unformulated hsiRNAs 
in primary neurons
HTT10150 induced a concentration-dependent silencing at 72 
hours and 1 week after unformulated addition to either primary 
cortical or primary striatal neurons isolated from FVB/NJ mice 
(Figure 3a). At 1.25 µmol/l, HTT10150 induced maximal silenc-
ing, reducing both Htt mRNA levels and HTT protein levels by as 
much as 70 and 85%, respectively  (Figure 3a–c for original west-
erns). HTT10150 hsiRNA did not affect the expression levels of 
housekeeping controls (Ppib and Tubb1) or the overall viability of 
primary neuronal cells, as measured by the alamarBlue assay, 
up to a 2 µmol/l concentration (Supplementary Figure S2). 
Similar results were obtained with another hsiRNA target-
ing Htt mRNA (Figure 3c), supporting that the observed 
phenomena is not unique to HTT10150. These experiments, 
in conjugation with the results seen from targeting Ppib  
(Figure 1b), indicate that a diversity of genes and target 
sequences can be silenced by hsiRNAs in primary neurons 
simply upon direct addition of compounds into cellular media.
Since loaded RISC has a typical half-life of weeks,38 silenc-
ing is expected to be long lasting in nondividing cells. To eval-
uate duration of silencing after a single HTT10150 treatment 
of primary cortical neurons, Htt mRNA levels were measured 
at 1-, 2-, and 3-week intervals (Figure 3d). A single treatment 
Figure 3 HTT10150 shows dose-dependent silencing of huntingtin by passive uptake in primary neurons. (a) Huntingtin mRNA levels 
in primary striatal (black) or cortical (gray) neurons 1 week after treatment with the indicated concentrations of HTT10150. Huntingtin mRNA 
levels were normalized to Ppib mRNA. Data are expressed as percent of untreated control (n = 3 wells, mean ± SD). NTC, nontargeting control 
(1.25 µmol/l). (b) Huntingtin protein levels in primary neurons 1 week after treatment with the indicated concentrations of HTT10150. Huntingtin 
and β-tubulin proteins were quantified by densitometry of western blots, and huntingtin protein levels were normalized to β-tubulin. Data are 
expressed relative to the level of huntingtin protein in untreated control cells. (n = 5 neuronal preparations from separate pups, mean ± SD). 
NTC, nontargeting control (1.25 µmol/l). Graph of silencing in primary cortical neurons after 1 week is representative, results confirmed in 
five separate experiments. (c) Original western blots from graph in b. Primary cortical neurons were cultured from five individual pups (#1–5) 
and incubated with HTT10150 at concentrations shown for 1 week. Huntingtin protein levels were detected by western blot using antibody 
AB1 (Huntingtin 1–17). NTC, nontargeting control. (d) Primary neurons were incubated with HTT10150 at concentrations shown, for 1, 2, and 
3 weeks. Level of huntingtin mRNA was measured using QuantiGene (Affymetrix) normalized to housekeeping gene, Ppib (cyclophillin B), 
and presented as percent of untreated control (n = 3 wells, mean ± SD). NTC, nontargeting control (1.5 µmol/l). Graph of silencing in primary 
cortical neurons after 1 week is representative, results confirmed in five separate experiments. (e) Primary cortical neurons were incubated 
with two different Htt hsiRNA sequences HTT10150 and HTT10146 at concentrations shown for 72 hours. Level of huntingtin mRNA was 
measured using QuantiGene (Affymetrix) normalized to housekeeping gene, Ppib (cyclophillin B), and presented as percent of untreated 
control (n = 3 wells, mean ± SD). NTC, nontargeting control (1.5 µmol/l). Graph of HTT10150 silencing in primary cortical neurons after 72 
hours is representative, results confirmed in seven separate experiments.
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with hsiRNA induced Htt silencing that persisted for at least 
3 weeks, the longest time that primary cortical neurons can 
be maintained in culture. Together, these data demonstrate 
that hsiRNAs are a simple and straightforward approach for 
potent, specific, nontoxic, and long-term modulation of gene 
expression in primary neurons in vitro.
hsiRNA distribution in vivo in mouse brain after 
intrastriatal injection
Having shown that hsiRNAs effectively silence their targets 
in primary neurons in vitro, we sought to evaluate the ability 
of HTT10150 to silence Htt mRNA in the mouse brain in vivo. 
The distribution of HTT10150 was evaluated in perfused 
brain sections prepared 24 hours after intrastriatal injection 
with 12.5 µg Cy3-labeled hsiRNA in artificial cerebral spinal 
fluid (ACSF). We observed a steep gradient of fluorescence 
emanating from the injection site and covering most of the 
ipsilateral striatum (Figure 4a,b), while no fluorescence was 
visually detectable in the contralateral side of the brain. In 
high magnification images of the ipsilateral side, hsiRNAs 
appeared preferentially associated with the tissue matrix and 
fiber tracts. In addition, efficient internalization was observed 
Figure 4 A single intrastriatal injection of HTT10150 is localized to neurons and fiber tracts ipsilateral to the injection site after 24 
hours. Twenty-five micrograms of Cy3-HTT10150 (red) was unilaterally injected into the striatum of WT (FVB/NJ) mice. Brains were collected 
after 24 hours, paraffin embedded, and sectioned. (a) Tiled image of coronal brain section (×16). Majority of HTT10150 is localized at site of 
injection with sharp gradient of diffusion. (b) Tiled image of sagittal brain section (×16), injected side. (c) Image of coronal brain section (×40), 
injected side. (d) Image of coronal brain section (×60), injected side, with NeuN-stained neurons. (e)  NeuN-stained neurons from injected side 
(×60) zoomed in. Solid arrow, NeuN staining. Open arrow, Cy3-HTT10150 punctae in perinuclear space. Images are representative, results 
confirmed in two separate experiments.
a
c d e
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Figure 5 HTT10150 effectively silences huntingtin mRNA ipsilateral to the site of injection. HTT10150 was unilaterally injected into the 
striatum of WT (FVB/NJ) mice (2 µl). Mice were sacrificed at 5 days. Brains were sliced into 300-µm sections and six 2-mm punch biopsies 
of the (a) striatum and (b) cortex were collected from both ipsilateral and contralateral sides. Level of huntingtin mRNA was measured using 
QuantiGene (Affymetrix) normalized to housekeeping gene, Ppib (cyclophillin B), and presented as percent of untreated control (n = 8 mice, 
mean ± SD, three biopsies per region). P values are all calculated for each dose group relative to NTC by Two-way repeated-measures analysis 
of variance: 25 µg striatum, P < 0.0001; 12.5 µg striatum, P < 0.0001, P = 0.0002; 6.3 µg cortex, P = 0.0009. NTC, nontargeting control.
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in a majority of cell bodies (Figure 4c,d). Consistent with 
in vitro studies, we observed Cy3-labeled hsiRNA in neuronal 
processes and as punctae in the perinuclear space of multiple 
cell types, including NeuN-positive neurons39,40  (Figure 4d,e). 
In summary, a single intrastriatal injection delivers hsiRNA to 
neurons in the striatum of the injected side.
hsiRNA effectively silences Htt in vivo with minimal 
cytotoxicity or immune activation
To measure HTT10150 efficacy in vivo, we performed 
 dose-response studies in wild type FVB/NJ mice injected 
intrastriatally with 3.1, 6.3, 12.5, or 25 µg of HTT10150. 
As controls, we injected mice with a non-targeting control 
hsiRNA (NTC), ACSF, or PBS. In punch biopsies taken from 
the ipsilateral and contralateral striatum, HTT10150 reduced 
Htt mRNA levels in a dose-dependent manner (Figure 5a).
This experiment was repeated several times with similar 
results. The Htt mRNA is significantly reduced in the ipsilat-
eral side of striatum in all experiments. We observed robust 
dose-dependent silencing with up to 77% (one-way analysis 
of variance, P < 0.0001) reduction in Htt mRNA expression 
levels at the highest dose. Interestingly we observe statisti-
cally significant, but less pronounced silencing in the con-
tralateral striatum and the cortex. The silencing reaches 
statistical significance with both one-way and two-way analy-
sis of variance (values for two-way analysis of variance are 
presented in Figure 5). While some level of fluorescence is 
detectable in these brain regions with high laser intensity, it 
is very close to the tissue auto-fluorescence and thus is not 
reported here. We will be investigating this phenomenon fur-
ther, but it is clear that the level of silencing is at least correla-
tive to the sharp gradient of diffusion from the injection site.
Finally, Htt mRNA silencing is observed with HTT10150 but 
not with NTC or ACSF (Figure 5). In addition, the HTT10150 
does not affect expression of several housekeeping genes 
(PPIB, HPRT). In combination, this is indicative of Htt mRNA 
silencing being caused by HTT10150 hsiRNA and not by 
 off-target effects.
Nucleic acids, including siRNAs, are potent stimulators 
of the innate immune response,41 but extensive chemical 
modifications, like 2′-O-methyl, are expected to suppress the 
immunostimulatory effects of siRNAs in vitro and in vivo.42 
To assess innate immune response activation by hsiRNAs 
in vivo, we quantified IBA-1-positive microglial cells in brain 
sections from mice injected with 12.5 µg HT10150 or artifi-
cial CSF. IBA-1 is specific to microglial cells and is upregu-
lated following injury to the brain, allowing us to distinguish 
between resting and activated microglia.43–45 In the case of a 
major innate immune response, an increase of 200–300% in 
total microglia is customary.46 Total microglia counts showed 
only a 25% increase in the ipsilateral striatum at 5 days 
post-injection indicating a lack of any major inflammatory 
response (Supplementary Figure S3). Thus, the observed 
activation is relatively minor but reaches statistical signifi-
cance, indicating some level of response. Levels of innate 
immune response might be more pronounced immediately 
Figure 6 HTT10150 shows a twofold increase in microglial activation at the site of injection. HTT10150 was unilaterally injected into the 
striatum of WT (FVB/NJ) mice. Brains were collected after (b) 6 hours and (a, c) 5 days fixed, sectioned, and stained with antibodies against 
IBA-1. (a) Representative images of activated (black arrow) and resting (open arrow) after injection of 12.5 µg HTT10150 and ACSF 5 days 
post-injection, ×40 magnification. (b) Quantification of activated and resting microglia 6 hours post-injection of ACSF (n = 6 mice, mean ± SD) 
and 12.5 µg HTT10150 (n = 3 mice, mean ± SD). P values calculated by unpaired t-test, t = 9.996, df = 7: ACSF versus HTT10150 activated 
microglia ipsilateral striatum, P = 0.0239. ACSF versus HTT10150 activated microglia contralateral striatum, P < 0.0001. (c) Quantification 
of activated and resting microglia 5 days postinjection of ACSF (n = 4 mice, mean ± SD) and 12.5 µg HTT10150 (n = 3 mice, mean ± SD). 
Images are representative, results confirmed in separate images of all injected brains. P values calculated by unpaired t-test, t = 2.700, df = 5: 
ACSF versus HTT10150 activated microglia ipsilateral striatum P = 0.0428.
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following compound administration. To assess the level of 
stimulation in more detail, we separately evaluated the num-
ber of activated and resting microglia at both 6 hours and 5 
days post-injection. At 6 hours post-injection, we observed a 
significant increase in the number of activated microglia in 
the injected side of the brain with both ACSF and HTT10150. 
The injection event itself causes trauma and induces a major 
increase in activated microglia (ninefold) compared to the 
contralateral side of the brain (Figure 6b).12,47 In the pres-
ence of HTT10150, the number of activated microglia was 
additionally increased twofold compared to ACSF, indicating 
enhancement of trauma-related microglia activation in the 
presence of oligonucleotide, although the relative contribu-
tion of the oligonucleotide to the trauma-related induction is 
minor. HTT10150-treated mice also showed some elevation 
of activated microglia in the contralateral striatum 6 hours 
post-injection (Figure 6b); however, after 5 days, all changes 
in number of microglia in the contralateral side of the brain 
disappeared (Figure 6a,c for representative images), sug-
gesting that HTT10150-dependent activation of microglia in 
the contralateral striatum is transient.
Despite the mild immune stimulation in the brains of ani-
mals injected with HTT10150, we did not observe any overall 
significant reduction of DARPP-32, an established marker 
for striatal neuron viability48 (Figure 7). The only observed 
effect was at a small area directly around the injection site in 
animals treated with 25 µg HTT10150 (Supplementary Fig-
ure S4). Taken together, our data show that a single intrastria-
tal injection of hsiRNA induces potent gene silencing with a 
mild immune response and minimal neuronal toxicity in vivo.
Discussion
Simple, effective, and nontoxic delivery of synthetic oli-
gonucleotides to primary neurons and brain tissue rep-
resents a challenge to the use of RNAi as a research tool 
and therapeutic for neurodegenerative diseases like HD.7 
We have shown that hsiRNAs elicit potent silencing in pri-
mary neurons in culture, without effect on housekeeping 
gene expression, and with minimal toxicity at effective doses 
Additionally, a non-targeting control hsiRNA did not silence 
any of the mRNAs tested (Htt, Ppib, Hprt), suggesting that 
these compounds are both sequence specific and on-target. 
Interestingly, the level of silencing is more pronounced on the 
protein level (>90%) compared to the mRNA level (>70%). 
The mRNA plateau effect is reproducible and is specific to 
Htt mRNA, as housekeeping genes like Ppib can be silenced 
by 90%. One potential explanation is that some fraction of 
Figure 7 HTT10150 shows no toxicity in DARPP-32-positive neurons around the site of injection. HTT10150 was unilaterally injected 
into the striatum of WT (FVB/NJ) mice. Brains were collected after 5 days, fixed, sectioned, and stained with antibodies against DARPP-32 
(a–d). Representative image of striatum after injection of (a,b) ACSF, full brain scan and ×60 magnification or (c,d) 12.5 µg HTT10150, full 
brain scan and ×60 magnification. (a) Quantification of DARPP-32–positive neurons (n = 3 mice, mean ± SD). Images are representative 
results confirmed in separate images of all injected brains.
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huntingtin mRNA is translationally inactive and poorly acces-
sible by RNAi machinery. We are continuing to investigate 
this phenomenon. Silencing in primary neurons persists for 
multiple weeks after a single administration, consistent with 
the expected half-life of active RISC.49 Moreover, efficient 
intracellular delivery does not require the use of lipids or viral 
packaging.
Currently, the most impressive in vivo modulation of Htt 
mRNA expression is demonstrated with 2′-O-methoxyethyl 
GapmeR antisense oligonucleotides. A single injection of 50 
µg of antisense oligonucleotides or infusion of around 500 µg 
results in potent and specific Htt mRNA silencing and marked 
improvement in multiple phenotypic endpoints.23,50–52 How-
ever, 2′-O-methoxyethyl GapmeR antisense oligonucleotides 
are not readily commercially available making them inacces-
sible for the majority of academic labs.
Here, we show Htt mRNA silencing in the ipsilateral stria-
tum and cortex, two brain areas significantly affected in HD 
disease progression, with a single intrastriatal injection. As 
a considerably reduced level of silencing was observed on 
the contralateral side of the brain, bilateral injections might 
be necessary to promote equal gene silencing in both 
hemispheres.
The limited distribution profile observed in vivo restricts 
immediate adoption of this technology for use in larger brains 
and eventually as a therapeutic for neurodegenerative dis-
ease. Tissue distribution can be improved by tailoring the 
chemical scaffold (e.g., number and type of sugar modifica-
tions, position of phosphorothioate linkages) or by changing 
the conjugation moiety to promote receptor-mediated cel-
lular internalization. Formulation of hsiRNA in exosomes, 
exosome-like liposomes, or shielding the compounds with 
polyethylene glycol may also provide an alternative strategy 
to improve tissue distribution.53,54
Here, we describe a class of self-delivering therapeutic oli-
gonucleotides capable of targeted, nontoxic, and efficient Htt 
gene silencing in primary neurons and in vivo. This chemical 
scaffold can be specifically adapted to many different targets 
to facilitate the study of neuronal gene function in vitro and 
in vivo. The development of an accessible strategy for genetic 
manipulation in the context of a native, biological environ-
ment represents a technical advance for the study of neuro-
nal biology and neurodegenerative disease.
Materials and methods
hsiRNA design. We designed and synthesized a panel of 
94 hsiRNA compounds (Supplementary Table S1) target-
ing the human huntingtin gene. These sequences span the 
gene and were selected to comply with standard siRNA 
design parameters24 including assessment of GC content, 
specificity and low seed compliment frequency,55 elimination 
of sequences containing miRNA seeds, and examination of 
thermodynamic bias.56,57
Oligonucleotide synthesis, deprotection, and purification. 
Oligonucleotides were synthesized using standard phos-
phoramidite, solid-phase synthesis conditions on a 0.2–1 
µmole scale using a MerMade 12 (BioAutomation, Irving, 
TX) and Expedite DNA/RNA synthesizer. Oligonucleotides 
with unmodified 3′ ends were synthesized on controlled pore 
glass (CPG) functionalized with long-chain alkyl amine and a 
Unylinker terminus (Chemgenes, Wilmington, MA). Oligonu-
cleotides with 3′-cholesterol modifications were synthesized 
on modified solid support (Chemgenes). Phosphoramidite 
solutions were prepared at 0.15 mol/l in acetonitrile for 2′-
TBDMS, 2′-O-methyl (Chemgenes), and Cy3 modifications 
or 0.13 mol/l for 2′-fluoro (BioAutomation) modifications. 
Phosphoramidites were activated in 0.25 mol/l 4,5-dicya-
noimidazole in acetonitrile. Detritylation was performed in 
3% dichloroacetic acid in dichloromethane for 80 seconds. 
Capping was performed in 16% N-methylimidazole in tetra-
hydrofuran and acetic anhydride:pyridine:tetrahydrofuran, 
(1:2:2, v/v/v) for 15 seconds. Oxidation was performed using 
0.1 mol/l iodine in pyridine:water:tetrahydrofuran (1:2:10, 
v/v/v).
The CPG was removed from the solid-phase column 
and placed in a polypropylene screw cap vial. Dimethylsulf-
oxide (100 µl) and 40% methylamine (250 µl) are added 
directly to the CPG and shaken gently at 65 °C for exactly 
16 minutes. The vial was cooled on dry ice before the cap 
was removed. The supernatant was transferred to another 
polypropylene screw cap vial, and the CPG was rinsed with 
two 150 µl portions of dimethylsulfoxide, which were com-
bined with original supernatant. Oligonucleotides without 
 2′-TBDMS-protecting groups were lyophilized. Oligonucle-
otides with  2′-TBDMS-protecting groups were desilylated by 
adding 375 µl triethylamine trihydrofluoride (~1.5 volumes 
relative to 40% methylamine) and incubated for exactly 
16 minutes at 65 °C with gentle shaking. Samples were 
quenched by transferring to a 15 ml conical tube containing 
2 ml of 2 mol/l triethylammonium acetate buffer (pH 7.0). The 
sample was stored at −80 °C until high-performance liquid 
chromatography purification.
Oligonucleotides were purified by reverse-phase 
 high-performance liquid chromatography on a Hamilton 
 PRP-C18 column (21 × 150 mm) using an Agilent Prostar 
325 high-performance liquid chromatography (Agilent, Santa 
Clara, CA). Buffer A 0.05 mol/l tetraethylammonium acetate 
with 5% acetonitrile, Buffer B 100% acetonitrile, with a gra-
dient of 0% B to 35% B over 15 minutes at 30 ml/minutes. 
Purified oligonucleotides were lyophilized to dryness, recon-
stituted in water, and passed over a Hi-Trap cation exchange 
column to exchange the tetraethylammonium counter-ion 
with sodium.
Cell culture. HeLa cells (ATCC, Manassas, VA; #CCL-2) 
were maintained in Dulbecco's Modified Eagle's Medium 
(Cellgro, Corning, NY; #10-013CV) supplemented with 10% 
fetal bovine serum (FBS; Gibco, Carlsbad, CA; #26140) and 
100 U/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA; 
#15140) and grown at 37 °C and 5% CO2. Cells were split 
every 2 to 5 days and discarded after 15 passages.
Preparation of primary neurons. Primary cortical neurons 
were obtained from FVB/NJ mouse embryos at embryonic 
day 15.5. Pregnant FVB/NJ females were anesthetized by 
intraperitoneal injection of 250 mg Avertin (Sigma, St Louis, 
MO; #T48402) per kg weight, followed by cervical dislocation. 
www.moleculartherapy.org/mtna
hsiRNAs Silence Htt in Neurons and Mouse Brain
Alterman et al.
9
Embryos were removed and transferred into a Petri dish with 
ice-cold Dulbecco's Modified Eagle's Medium/F12 medium 
(Invitrogen; #11320). Brains were removed, and meninges 
carefully detached. Cortices were isolated and transferred into 
a 1.5-ml tube with prewarmed papain solution for 25 minutes 
at 37 °C, 5% CO2, to dissolve tissue. Papain solution was pre-
pared by suspending DNase I (Worthington, Lakewood, NJ; 
#54M15168) in 0.5 ml Hibernate E medium (Brainbits, Spring-
field, IL; #HE), and transferring 0.25 ml DNase I solution to 
papain (Worthington, Lakewood, NJ; #54N15251) dissolved in 
2 ml Hibernate E medium and 1 ml Earle’s balanced salt solu-
tion (Worthington; #LK003188). After the 25-minute incuba-
tion, papain solution was replaced with 1 ml NbActiv4 medium 
(Brainbits;  #Nb4-500) supplemented with 2.5% FBS. Cortices 
were dissociated by repeated pipetting with a fire-polished, 
glass, Pasteur pipette. Cortical neurons were counted and 
plated at 1 × 106 cells per ml.
For live-cell imaging, culture plates were precoated with 
poly-l-lysine (Sigma; #P4707), and 2 × 105 cells were added 
to the glass center of each dish. For silencing assays, 
neurons were plated on 96-well plates precoated with 
 poly-l-lysine (BD BIOCOAT, Corning, NY; #356515) at 1 × 105 
cells per well. After overnight incubation at 37 °C, 5% CO2, an 
equal volume of NbActiv4 supplemented with anti-mitotics, 
0.484 µl/ml of UTP Na3 (Sigma; #U6625), and 0.2402 µl/ml 
of FdUMP (Sigma; #F3503), was added to neuronal cultures 
to prevent growth of nonneuronal cells. Half of the media 
volume was replaced every 48 hours until the neurons were 
treated with siRNA. Once the cells were treated, media was 
not removed, only added. All subsequent media additions 
contained antimitotics.
Direct delivery (passive uptake) of oligonucleotides. Cells 
were plated in Dulbecco's Modified Eagle's Medium contain-
ing 6% FBS at 10,000 cells per well in 96-well tissue culture 
plates. hsiRNA was diluted to twice the final concentration 
in OptiMEM (Gibco;  #31985-088), and 50 µl diluted hsiRNA 
was added to 50 µl of cells, resulting in 3% FBS final. Cells 
were incubated for 72 hours at 37 °C and 5% CO2. Based on 
previous experience, we know that 1.5 µmol/l active hsiRNA 
supports efficient silencing without toxicity. The primary 
screen for active Htt siRNAs, therefore, was performed at 1.5 
µmol/l compound, which also served as the maximal dose for 
in vitro dose–response assays.
hsiRNA lipid-mediated delivery. Cells were plated in Dulbec-
co's Modified Eagle's Medium with 6% FBS at 10,000 cells 
per well in 96-well tissue culture–treated plates. hsiRNA was 
diluted to four times the final concentration in OptiMEM, and 
Lipofectamine RNAiMAX Transfection Reagent (Invitrogen; 
#13778150) was diluted to four times the final concentration 
(final = 0.3 µl/25 µl/well). RNAiMAX and hsiRNA solutions 
were mixed 1:1, and 50 µl of the transfection mixture was 
added to 50 µl of cells resulting in 3% FBS final. Cells were 
incubated for 72 hours at 37 °C and 5% CO2.
mRNA quantification in cells and tissue punches. mRNA 
was quantified using the QuantiGene 2.0 Assay (Affymetrix; 
#QS0011). Cells were lysed in 250 µl diluted lysis mixture 
composed of 1 part lysis mixture (Affymetrix; #13228), 2 parts 
H2O, and 0.167 µg/µl proteinase K (Affymetrix; #QS0103) for 
30 minutes at 55 °C. Cell lysates were mixed thoroughly, and 
40 µl (~8,000 cells) of each lysate was added per well to a 
capture plate with 40 µl diluted lysis mixture without protein-
ase K. Probe sets were diluted as specified in the Affymetrix 
protocol. For HeLa cells, 20 µl human HTT or PPIB probe set 
(Affymetrix; #SA-50339, #SA-10003) was added to appropri-
ate wells for a final volume of 100 µl. For primary neurons, 
20 µl of mouse Htt or Ppib probe set (Affymetrix; #SB-14150, 
#SB-10002) was used.
Tissue punches (5 mg) were homogenized in 300 µl of 
Homogenizing Buffer (Affymetrix; #10642) containing 2 µg/µl 
proteinase K in 96-well plate format on a QIAGEN TissueLy-
ser II (Qiagen, Valencia, CA; #85300), and 40 µl of each lysate 
was added to the capture plate. Probe sets were diluted as 
specified in the Affymetrix protocol, and 60 µl of Htt or Ppib 
probe set was added to each well of the capture plate for a 
final volume of 100 µl. Signal was amplified according to the 
Affymetrix protocol. Luminescence was detected on either a 
Veritas Luminometer (Promega, Madison, WI; #998–9100) or 
a Tecan M1000 (Tecan, Morrisville, NC).
Western blot. Cell lysates (25 µg) were separated by SDS–
PAGE using 3–8% Tris-acetate gels (Life Technologies, Grand 
Island, NY; #EA03785BOX) and transferred to nitrocellulose 
using a TransBlot Turbo apparatus (BioRad, Hercules, CA; 
#1704155). Blots were blocked in 5% nonfat dry milk (BioRad; 
#1706404) diluted in Tris-buffered saline with 0.1%  Tween-20 
(TBST) for 1 hour at room temperature then incubated in 
N-terminal antihuntingtin antibody Ab158 diluted 1:2,000 in 
blocking solution overnight at 4 °C with agitation. After wash-
ing in TBST, blots were incubated in peroxidase-labeled 
antirabbit IgG (Jackson ImmunoResearch, West Grove, PA; 
#711035152) diluted in blocking buffer for 1 hour at room 
temperature, washed in TBST, and proteins were detected 
using SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific, Rockford, IL; #34080) and Hyperfilm ECL 
(GE Healthcare, Buckinghamshire, UK; #28906839). Blots 
were reprobed with anti-β tubulin antibody (Sigma; #T8328) 
as a loading control. Films were scanned with a flatbed scan-
ner (Epson Perfection V750 Pro; Epson, Long Beach, CA), 
and densitometry was performed using NIH ImageJ software 
to determine total intensity of each band. The huntingtin sig-
nal was divided by the tubulin signal to normalize to protein 
content, and percent of untreated control was determined for 
each set of samples (N = 5).
Live cell imaging. To monitor live cell hsiRNA uptake, 
cells were plated at a density of 2 × 105 cells per 35-mm 
 glass-bottom dish. Cell nuclei were stained with NucBlue 
(Life Technologies; #R37605) as indicated by the manufac-
turer. Imaging was performed in phenol red-free NbActiv4 
(Brainbits; #Nb4-500). Cells were treated with 0.5 µmol/l 
Cy3-labeled hsiRNA, and live cell imaging was performed 
over time. All live cell confocal images were acquired with a 
Leica DM IRE2 confocal microscope using 63x oil immersion 
objective (Buffalo Grove, IL), and images were processed 
using ImageJ (1.47v) software.
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Stereotaxic injections. FVB/NJ mice (50% male and 50% 
female for each dose group, 6–8 weeks old) were deeply 
anesthetized with 1.2% Avertin (Sigma; #T48402) and micro-
injected by stereotactic placement into the right striatum 
(coordinates relative to bregma: 1.0 mm anterior, 2.0 mm 
lateral, and 3.0 mm ventral). For both toxicity (DARPP-32 
staining) and efficacy studies, mice were injected with either 
PBS or artificial CSF (2 µl per striata), 12.5 µg of nontarget-
ing hsiRNA (2 µl of 500 µmol/l stock per striata), 25 µg of 
HTT10150 hsiRNA (2 µl of 1 mmol/l stock per striata), 12.5 
µg of HTT10150 hsiRNA (2 µl of 500 µmol/l stock per striata), 
6.3 µg of HTT10150 hsiRNA (2 µl of 250 µmol/l stock per stri-
ata), or 3.1 µg of HTT10150 hsiRNA (2 µl of 125 µmol/l stock 
per striata). For toxicity studies, n = 3 mice were injected per 
group, and for efficacy studies, n = 8 mice were injected per 
group. Mice were euthanized 5 days post-injection, brains 
were harvested, and three 300-µm coronal sections were 
prepared. From each section, a 2-mm punch was taken from 
each side (injected and noninjected) and placed in RNAlater 
(Ambion, Carlsbad, CA; #AM7020) for 24 hours at 4 °C. Each 
punch was processed as an individual sample for Quan-
tigene 2.0 assay analysis (Affymetrix) and averaged for a 
single animal point. All animal procedures were approved by 
the University of Massachusetts Medical School Institutional 
Animal Care and Use Committee (protocol number A-2411).
Immunohistochemistry/immunofluorescence. Mice were inje-
cted intrastriatally with 12.5 µg of Cy3-labeled hsiRNA. After 24 
hours, mice were sacrificed and brains were removed, embed-
ded in paraffin, and sliced into 4-µm sections that were mounted 
on glass slides. Sections were deparaffinized by incubating in 
Xylene twice for 8 minutes. Sections were rehydrated in serial 
ethanol dilutions (100%, 95%, and 80%) for 4 minutes each, 
and then washed twice for 2 minutes with PBS.
For NeuN staining,39,40 slides were boiled for 5 minutes in 
antigen retrieval buffer (10 mmol/l Tris/ 1mmol/l EDTA (pH 
9.0)), incubated at room temperature for 20 minutes, and 
then washed for 5 minutes in PBS. Slides were blocked in 
5% normal goat serum in PBS containing 0.05% Tween 20 
(PBST) for 1 hour and washed once with PBST for 5 min-
utes. Slides were incubated with primary antibody (Millipore, 
Taunton, MA; MAB377, 1:1,000 dilution in PBST) for 1 hour 
and washed three times with PBST for 5 minutes. Slides 
were then incubated with secondary antibody (Life Technolo-
gies; #A11011, 1:1000 dilution in PBST) for 30 minutes in 
the dark and washed three times with PBST for 5  minutes 
each. Slides were then counterstained with 250 ng/ml 
4',6- diamidino-2-phenylindole (Molecular Probes, Life Tech-
nologies; #D3571) in PBS for 1 minute and washed three 
times with PBS for 1 minute. Slides were mounted with 
mounting medium and coverslips and dried overnight before 
imaging on a Leica DM5500 microscope fitted with a DFC365 
FX fluorescence camera.
For toxicity studies, injected brains were harvested after 5 
days. For microglial activation studies, brains were harvested 
after 6 hours or 5 days. Extracted, perfused brains were sliced 
into 40-µm sections on the Leica 2000T Vibratome (Leica 
Biosystems, Wetzlar, Germany) in ice-cold PBS. Every sixth 
section was incubated with DARPP-32 (Abcam, Cambridge, 
UK; #40801; 1:10,000 in PBS) or IBA-1 (Wako; #019-19741; 
1:1,000 in PBS) antibody, for a total of nine sections per brain 
and eight images per section (four per hemisphere). IBA-1 
sections were incubated in blocking solution (5% normal 
goat serum, 1% bovine serum albumin, 0.2% Triton-X-100, 
and 0.03% hydrogen peroxide in PBS) for 1 hour, and then 
washed with PBS. Sections were incubated overnight at 4 °C 
in primary antibody, anti-Iba1 (polyclonal rabbit  anti-mouse/
human/rat; dilution: 1:1,000 in blocking solution) (Wako; 
#019-19741). Sections were then stained with goat antirab-
bit secondary antibody (1:200 dilution) (Vector Laboratories, 
Burlingame, CA), followed by a PBS wash, the Vectastain 
ABC Kit (Vector Laboratories), and another PBS wash. IBA-1 
was detected with the Metal Enhanced DAB Substrate Kit 
(Pierce, Rockford, IL). For DARPP32 staining, sections were 
washed for 3 minutes in 3% hydrogen peroxide, followed by 
20 minutes in 0.2% TritonX-100 and 4 hours in 1.5% normal 
goat serum in PBS. Sections were incubated overnight at 4 °C 
in DARPP32 primary antibody (1:10,000 dilution) (Abcam; 
#40801) made up in 1.5% normal goat serum. Secondary 
antibody and detection steps were conducted as described 
for IBA-1 staining. DARPP-32 sections were mounted and 
visualized by light microscopy with 20× objective on a Nikon 
Eclipse E600 with a Nikon Digital Sight DSRi1 camera (Nikon, 
Tokyo, Japan). The number of DARPP-32-positive neurons 
was quantified manually using the cell counter  plug-in on 
ImageJ for tracking. Activated microglia were quantified by 
morphology of IBA-1-positive cells42–45
 from the same num-
ber of sections captured with 40× objective. Counting of 
both IBA-1- and DARPP-32-positive cells was blinded. Coro-
nal section images were taken with a Coolscan V-ED LS50 
35-mm Film Scanner (Nikon, Tokyo, Japan).
Statistical analysis. Data were analyzed using GraphPad 
Prism 6 software (GraphPad Software, Inc., San Diego, CA). 
Concentration-dependent IC50 curves were fitted using a 
log(inhibitor) versus response–variable slope (four param-
eters). The lower limit of the curve was set at zero, and the 
upper limit of the curve was set at 100. For each independent 
mouse experiment, the level of knockdown at each dose was 
normalized to the mean of the control group (the noninjected 
side of the PBS or artificial CSF groups). In vivo data were 
analyzed using a two-way repeated-measures analysis of 
variance with Tukey’s multiple comparisons test for dose and 
side of brain. Differences in all comparisons were considered 
significant at P values less than 0.05 compared with the NTC- 
injected group. P values reported represent significance of 
the entire dose group relative to NTC and are not specific to 
the ipsilateral or contralateral side. For microglial activation, 
significance was calculated using a parametric, unpaired, 
two-tailed t-test for comparison between dose groups, and 
paired t-test for comparison between ipsilateral and contra-
lateral hemispheres within the same dose group.
Supplementary material
Figure S1. Active hsiRNAs silence huntingtin mRNA in a 
concentration dependent manner in HeLa cells.
Figure S2. HTT10150 does not affect primary cortical 
 neuron viability.
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Figure S3. HTT10150 causes a slight increase in total 
 resting microglia 5 days post injection.
Figure S4. HTT10150 shows limited toxicity at the site of 
injection at the 25 µg dose.
Table S1. Detailed sequence, chemical modification 
 patterns, and efficacy of hsiRNAs.
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